AstraZeneca to acquire Fusion Pharmaceuticals to boost cancer radioconjugate development
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of ... Read More
AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio
AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments for rare endocrine diseases, in a deal ... Read More
Gilead Sciences to acquire CymaBay Therapeutics to enhance liver disease portfolio
In a significant move within the biopharmaceutical industry, Gilead Sciences, Inc. (Nasdaq: GILD) has confirmed its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a ... Read More
Jazz Pharmaceuticals to acquire Redx Pharma’s KRAS inhibitor program to expand oncology pipeline
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) have entered into a definitive agreement, marking a significant milestone in the development of ... Read More
Novartis announces takeover bid for MorphoSys AG to boost oncology pipeline
In a significant move within the pharmaceutical industry, Novartis has entered into an agreement to launch a voluntary public takeover offer to acquire MorphoSys AG, ... Read More
AVROBIO announces merger with Tectonic Therapeutic in significant all-stock deal
AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc., a biotechnology firm specializing in GPCR (G-protein coupled receptor)-targeted therapeutic proteins, have announced a definitive merger agreement. ... Read More
Sandoz to acquire biosimilar CIMERLI from Coherus BioSciences to expand ophthalmology portfolio
In a significant development within the pharmaceutical and healthcare industry, Sandoz, a global leader in generic and biosimilar medicines, announced its strategic acquisition of the ... Read More
Merck to acquire Harpoon Therapeutics for $680m to strengthen oncology pipeline
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) have entered a definitive agreement where Merck ... Read More
GSK to acquire Aiolos Bio to expand respiratory treatment portfolio
GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) have announced a significant agreement, where GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focusing on ... Read More
AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash payment of $1.0 billion, representing a 62% ... Read More